替雷利珠单抗联合复方苦参注射液辅助治疗晚期胃癌化疗患者的临床效果分析OA

Objective To analyze the clinical efficacy of Tislelizumab combined with Compound Kushen injection(CKI)as adjuvant therapy in patients with advanced gastric cancer undergoing chemotherapy.Methods A total of 106 patients with advanced gastric cancer admitted to Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Hebei Province,from July 2021 to July 2024 were selected.They were divided into the conventional group and the Compound group at a ratio of 1:1 using a random number table.Both groups were treated with the XELOX chemotherapy regimen(Oxaliplatin combined with Capecitabine).On this basis,the conventional group was treated with Tislelizumab,while the Compound group was treated with Tislelizumab combined with CKI.The objective response rate(ORR),tumor regression grade(TRG),adverse reactions,1-year survival rate,and median progression-free survival(PFS)were compared between the two groups.The expressions of T lymphocyte subsets,carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA),miR-369,miR-1323,Revised Piper Fatigue Scale(PFS-R),European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30),and Chinese-strategies used by people to promote health(C-SUPPH)scores before and after treatment were compared.Results The ORR and the total effective rate of TRG in the Compound group were 60.38%(32/53)and 64.15%(34/53)respectively,which were higher than those of the conventional group[39.62%(21/53)and 41.51%(22/53)](P<0.05).After 2 and 4 treatment courses,the expression levels of peripheral blood CD3+,CD4+,CD4+/CD8+and miR-369 in the Compound group were higher than those in the conventional group,while the expression levels of serum CA19-9,CEA and miR-1323 were lower than those in the conventional group(P<0.05).After 2 and 4 treatment courses,the PFS-R score of the Compound group was lower than that of the conventional group,while the EORTC QLQ-C30 score was higher than that of the conventional group(P<0.05).There was no significant difference in the C-SUPPH score between the two groups(P>0.05),nor significant difference in the total incidence of adverse reactions between the two groups(P>0.05).After 1-year follow-up,1 patient was lost to follow-up in each group.The 1-year survival rate of the Compound group was 69.23%(36/52),which was higher than that of the conventional group[50.00%(26/52)],and the median PFS was longer than that of the conventional group(P<0.05).Conclusion For patients with advanced gastric cancer undergoing chemotherapy,the use of Tislelizumab combined with CKI can increase the ORR,lower the levels of tumor markers,regulate the expression of miR-1323 and miR-369,and improve TRG,immune function,cancer-related fatigue and quality of life,without significantly increasing adverse reactions.In the meantime,it can prolong the median PFS of patients and increase the 1-year survival rate.